01:55 PM EDT, 06/12/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Thursday it will move its subcutaneous and oral amycretin candidate for weight management into phase 3 clinical development.

The phase 3 development of the GLP-1 candidate for adults with obesity is based on feedback from regulators on completed clinical trials, according to a statement.

The company said it plans to begin the phase 3 program in Q1 2026.

Shares were up 2.5% in recent trading.

Price: 80.85, Change: +2.12, Percent Change: +2.69